Key TakeawaysZacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture appears to brighten in 2025.The healthcare company has beaten earnings estimates in three of the past four quarters.Register now to see our 7 Best Stocks for the Next 30 Days report - free today!AstraZeneca (AZN) will report its third-quarter earnings on Nov. 12, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.04 billion and $1.01 per share, respectiv ...

Company News - AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an insurance fraud case [1] - AstraZeneca China President Leon Wang is cooperating with Chinese authorities [1] - In September, five current and former AstraZeneca employees were detained by police in China in connection with multiple investigations [1] - Dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case [2] - The company stated that if requested, it will fully cooperate with the Chinese authorities [2] - Five current and former AstraZeneca employees were detained by police in China in September in connection with alleged violations of data privacy laws and for importing an unapproved cancer drug [3] - AstraZeneca employs roughly 16,000 workers in China and has operated there since 1993 [3] Stock Performance - U S -listed shares of AstraZeneca fell more than 7% Tuesday to close at $66 27 [3] - The shares are down 1 6% in 2024 [3]

Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial focus on severe respiratory disorders.Piper Sandler initiated coverage on Upstream Bio with an Overweight rating and a price target of $75.William Blair has also initiated coverage of Upstream Bio with an Outp ...

The price could be right for these stocks.A low share price doesn't necessarily mean a stock is valued attractively. For example, you wouldn't invest in a company that markets oceanfront property in Arizona regardless of how low its share price was. However, prices per share can matter to investors who don't have a lot of cash to put to work.If you're in that group, you're in luck. Three Fool.com contributors have identified what they view as magnificent stocks trading at under $100 to buy in November. Here ...

Astrazeneca (AZN) closed at $71.42 in the latest trading session, marking a +0.38% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.41%. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 0.8%. Heading into today, shares of the pharmaceutical had lost 8.7% over the past month, lagging the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97% in that time. Investors will be eagerly watching for the performanc ...

In the latest trading session, Astrazeneca (AZN) closed at $75.05, marking a -1.12% move from the previous day. This change lagged the S&P 500's daily loss of 0.03%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, added 0.56%. The pharmaceutical's stock has dropped by 2.92% in the past month, exceeding the Medical sector's loss of 4.4% and lagging the S&P 500's gain of 1.39%. The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming ...

Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday. The company agreed with AstraZeneca Plc's AZN Alexion for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson's disease. Monopar will be responsible for all future global development and commercialization activities. Also Read: Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity in Monopar. Future p ...

BOSTON, Mass. and SHANGHAI, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase 2b program. VISTA (NCT06579092) and SOLSTICE (NCT06579 ...

AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for their drug Wainzua (eplontersen) for treating hereditary transthyretin-mediated amyloidosis, commonly called hATTR-PN or ATTRv-PN.If the European Commission approves Wainzua, it will become the only medicine approved for treating ATTRv-PN that can be self-administered monthly via an auto-injector in the European Union.Wainzua was approved by the name of Wai ...

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with p ...